Deciphering the concentration-dependent modulation effect of CT16 on the human a7 nicotinic receptor: Insights from molecular dynamics simulation

Abstract

Alzheimer's disease (AD) is closely linked to the accumulation of amyloid-beta peptides (Aβ), which impair synaptic plasticity and contribute to cognitive decline. Among the fragments of Aβ, the CT16 peptide (the equivalent of Aβ16, derived from soluble amyloid precursor protein α, sAPPα) has been shown to interact with the α7 nicotinic acetylcholine receptor (α7nAChR), potentially enhancing synaptic plasticity. However, the concentration-dependent modulation of CT16 on α7nAChR and its underlying mechanisms remain poorly understood. We employ molecular dynamics simulations to investigate how varying concentrations of CT16 affect the conformation and function of the α7nAChR, and establishes the proportional relationship between CT16 concentration and α7nAChR receptor function regulation at the molecular level, finding a stoichiometric ratio of 1:3 for maximum activation of α7nAChR by CT16, and establishing the first demonstration that the constriction geometry of the pore within extracellular domain (specifically its minimal cross-sectional area) serves as the dominant structural determinant for ion permeation pathways at stoichiometric CT16:α7nAChR binding (1:1 ratio), a phenomenon contrasting sharply with scenarios at higher ratios (CT16:α7nAChR > 1:1). The presence of CT16 not only induces significant conformational changes, stabilizes specific receptor regions, but also modulates the ion channel's pore geometry in a concentration-dependent manner. These findings shed light on the potential role of CT16 in regulating synaptic plasticity and offer theoretical insights into its dual role as a positive allosteric modulator at low concentrations and an inhibitor at higher concentrations, which may have implications for therapeutic strategies targeting α7nAChR in AD and other neurodegenerative diseases.

Keywords

CT16 peptides / α7nAChR receptor / Concentration-dependent modulation / Allosteric mechanism / Implications for therapeutic strategies

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

CRediT authorship contribution statement

Chuanbo Wang: Writing - original draft, Visualization, Validation, Methodology, Investigation, Formal analysis, Data curation, Conceptualization. Jinfei Mei: Investigation, Formal analysis. Mengke Jia: Validation, Methodology, Investigation, Formal analysis. Sajjad Ahmad: Validation. Zijian Liu: Validation. Hongqi Ai: Writing - review & editing, Supervision, Resources, Project administration, Funding acquisition, Conceptualization.

Acknowledgements

This work was supported by the Shandong Provincial Natural Science Foundation (ZR2022MB073) of China.

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.chphma.2025.07.001.

References

[1] K.N. Hascup, C.A. Findley, J. Britz, N. Esperant-Hilaire, S.O. Broderick, K. Delfino, S. Tischkau, A. Bartke, E.R. Hascup, Riluzole attenuates glutamatergic tone and cognitive decline in $\mathrm{A} \beta \mathrm{PP} / \mathrm{PS} 1$ mice, J. Neurochem. 156 (2021) 513-523, doi:10.1111/jnc.15224.

[2] D.J. Selkoe, Alzheimer's disease is a synaptic failure, Science 298 (2002) 789-791, doi:10.1126/science. 1074069.

[3] D.A. Gusnard, M.E. Raichle, Searching for a baseline: Functional imaging and the resting human brain, Nat. Rev. Neurosci. 2 (2001) 685-694, doi:10.1038/35094500.

[4] M. Sastre, H. Steiner, K. Fuchs, A. Capell, G. Multhaup, M.M. Condron, D.B. Teplow, C. Haass, Presenilin-dependent $\gamma$-secretase processing of $\beta$-amyloid precursor protein at a site corresponding to the S3 cleavage of Notch, EMBO Rep. 2 ( 2001) 835-841, doi:10.1093/embo-reports/kve180.

[5] A. Weidemann, S. Eggert, F.B.M. Reinhard, M. Vogel, K. Paliga, G. Baier, C.L. Masters, K. Beyreuther, G. Evin, A novel $\varepsilon$-cleavage within the transmembrane domain of the Alzheimer amyloid precursor protein demonstrates homology with Notch processing, Biochemistry 41 (2002) 2825-2835, doi:10.1021/bi015794o.

[6] C. Haass, C. Kaether, G. Thinakaran, S. Sisodia, Trafficking and proteolytic processing of APP, Cold Spring Harb, Perspect. Med. 2 (2012) a006270, doi:10.1101/cshperspect.a006270.

[7] S. Ludewig, M. Korte, Novel insights into the physiological function of the APP (gene) family and its proteolytic fragments in synaptic plasticity, Front. Mol. Neurosci. 9 (2017) 161, doi:10.3389/fnmol.2016.00161.

[8] D. Kögel, T. Deller, C. Behl, Roles of amyloid precursor protein family members in neuroprotection, stress signaling and aging, Exp. Brain Res. 217 (2012) 471-479, doi:10.1007/s00221-011-2932-4.

[9] H.C. Rice, D. de Malmazet, A. Schreurs, S. Frere, I. Van Molle, A.N. Volkov, E. Creemers, I. Vertkin, J. Nys, F.M. Ranaivoson, D. Comoletti, J.N. Savas, H. Remaut, D. Balschun, K.D. Wierda, I. Slutsky, K. Farrow, B. De Strooper, J. de Wit, Secreted amyloid- $\beta$ precursor protein functions as a $\mathrm{GABA}_{\mathrm{B}} \mathrm{R} 1 \mathrm{a}$ ligand to modulate synaptic transmission, Science 363 (2019) aao4827, doi:10.1126/science.aao4827.

[10] M.C. Richter, S. Ludewig, A. Winschel, T. Abel, C. Bold, L.R. Salzburger, S. Klein, K. Han, S.W. Weyer, A.K. Fritz, B. Laube, D.P. Wolfer, C.J. Buchholz, M. Korte, U.C. Müller, Distinct in vivo roles of secreted APP ectodomain variants APPs a and APPs $\beta$ in regulation of spine density, synaptic plasticity, and cognition, EMBO J. 37 (2018) e201798335, doi:10.15252/embj. 201798335.

[11] K.G. Ma, Y.H. Qian, Alpha 7 nicotinic acetylcholine receptor and its effects on Alzheimer's disease, Neuropeptides 73 ( 2019) 96-106, doi:10.1016/j.npep.2018.12.003.

[12] A.V. Terry Jr., P.M. Callahan, a7 nicotinic acetylcholine receptors as therapeutic targets in schizophrenia: Update on animal and clinical studies and strategies for the future, Neuropharmacology 170 (2020) 108053, doi:10.1016/j.neuropharm.2020.108053.

[13] E. Portelius, U. Andreasson, J.M. Ringman, K. Buerger, J. Daborg, P. Buchhave, O. Hansson, A. Harmsen, M.K. Gustavsson, E. Hanse, D. Galasko, H. Hampel, K. Blennow, H. Zetterberg, Distinct cerebrospinal fluid amyloid beta peptide signatures in sporadic and PSEN1 A431E-associated familial Alzheimer's disease, Mol. Neurodegener. 5 (2010) 2, doi:10.1186/1750-1326-5-2.

[14] E. Portelius, A. Westman-Brinkmalm, H. Zetterberg, K. Blennow, Determination of beta-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitationmass spectrometry, J. Proteome Res. 5 (2006) 1010-1016, doi:10.1021/pr050475v.

[15] C. Haass, M. Willem, Secreted APP modulates synaptic activity: A novel target for therapeutic intervention? Neuron 101 ( 2019) 557-559, doi:10.1016/j.neuron.2019.01.058.

[16] J.A. Morrissey, B.G. Mockett, A. Singh, D. Kweon, S.M. Ohline, W.P. Tate, S.M. Hughes, W.C. Abraham, A C-terminal peptide from secreted amyloid precursor protein- a enhances long-term potentiation in rats and a transgenic mouse model of Alzheimer's disease, Neuropharmacology 157 (2019) 107670, doi:10.1016/j.neuropharm.2019.107670.

[17] D. Anni, E.M. Weiss, D. Guhathakurta, Y.E. Akdas, J. Klueva, S. Zeitler, M. AndresAlonso, T. Huth, A. Fejtova, A$\beta$1- 16 controls synaptic vesicle pools at excitatory synapses via cholinergic modulation of synapsin phosphorylation, Cell. Mol. Life Sci. 78 ( 2021) 4973-4992, doi:10.1007/s00018-021-03835-5.

[18] X. Gao, Y. Guan, C. Wang, M. Jia, S. Ahmad, M.F. Nouman, H. Ai, Specific interaction from different A$\beta$42 peptide fragments to a7nAChR : A study of molecular dynamics simulation, J. Mol. Model. 30 (2024) 233, doi:10.1007/s00894-024-06032-w.

[19] C.M. Noviello, A. Gharpure, N. Mukhtasimova, R. Cabuco, L. Baxter, D. Borek, S.M. Sine, R.E. Hibbs, Structure and gating mechanism of the a7 nicotinic acetylcholine receptor, Cell 184 (2021) 2121-2134.e13, doi:10.1016/j.cell.2021.02.049.

[20] S.M. Burke, M. Avstrikova, C.M. Noviello, N. Mukhtasimova, J.P. Changeux, G.A. Thakur, S.M. Sine, M. Cecchini, R.E. Hibbs, Structural mechanisms of a7 nicotinic receptor allosteric modulation and activation, Cell 187 (2024) 1160-1176.e21, doi:10.1016/j.cell.2024.01.032.

[21] Y. Zhao, S. Liu, Y. Zhou, M. Zhang, H. Chen, H. Xu, D. Sun, L. Liu, C. Tian, Structural basis of human a7 nicotinic acetylcholine receptor activation, Cell Res. 31 (2021) 713-716, doi:10.1038/s41422-021-00509-6.

[22] D. Bertrand, C.H. Lee, D. Flood, F. Marger, D. Donnelly-Roberts, Therapeutic potential of a7 nicotinic acetylcholine receptors, Pharmacol. Rev. 67 (2015) 1025-1073, doi:10.1124/pr.113.008581.

[23] H.R. Arias, Localization of agonist and competitive antagonist binding sites on nicotinic acetylcholine receptors, Neurochem. Int. 36 (2000) 595-645, doi:10.1016/s0197-0186(99)00154-0.

[24] G.T. Young, R. Zwart, A.S. Walker, E. Sher, N.S. Millar, Potentiation of a7 nicotinic acetylcholine receptors via an allosteric transmembrane site, Proc. Natl. Acad. Sci. U.S.A. 105 (2008) 14686-14691, doi:10.1073/pnas. 0804372105.

[25] C. Stokes, M. Treinin, R.L. Papke, Looking below the surface of nicotinic acetylcholine receptors, Trends Pharmacol. Sci. 36 (2015) 514-523, doi:10.1016/j.tips.2015.05.002.

[26] N. Andersen, J. Corradi, S.M. Sine, C. Bouzat, Stoichiometry for activation of neuronal a7 nicotinic receptors, Proc. Natl. Acad. Sci. U.S.A. 110 (2013) 20819-20824, doi:10.1073/pnas.1315775110.

[27] V. Echeverria, A. Yarkov, G. Aliev, Positive modulators of the a7 nicotinic receptor against neuroinflammation and cognitive impairment in Alzheimer's disease, Prog. Neurobiol. 144 (2016) 142-157, doi:10.1016/j.pneurobio.2016.01.002.

[28] T.L. Wallace, T.M. Ballard, B. Pouzet, W.J. Riedel, J.G. Wettstein, Drug targets for cognitive enhancement in neuropsychiatric disorders, Pharmacol. Biochem. Behav. 99 (2011) 130-145, doi:10.1016/j.pbb.2011.03.022.

[29] N.S. Philip, L.L. Carpenter, A.R. Tyrka, L.H. Price, Nicotinic acetylcholine receptors and depression: A review of the preclinical and clinical literature, Psychopharmacology 212 (2010) 1-12, doi:10.1007/s00213-010-1932-6.

[30] P. Dasgupta, W. Rizwani, S. Pillai, R. Kinkade, M. Kovacs, S. Rastogi, S. Banerjee, M. Carless, E. Kim, D. Coppola, E. Haura, S. Chellappan, Nicotine induces cell proliferation, invasion and epithelial-mesenchymal transition in a variety of human cancer cell lines, Int. J. Cancer 124 (2009) 36-45, doi:10.1002/ijc.23894.

[31] R. Kandimalla, P.H. Reddy, Therapeutics of neurotransmitters in Alzheimer's disease, J. Alzheimer's Dis. 57 (2017) 1049-1069, doi:10.3233/jad-161118.

[32] E. Cecon, J. Dam, M. Luka, C. Gautier, A.M. Chollet, P. Delagrange, L. Danober, R. Jockers, Quantitative assessment of oligomeric amyloid $\beta$ peptide binding to a7 nicotinic receptor, Br. J. Pharmacol. 176 (2019) 3475-3488, doi:10.1111/bph.14688.

[33] H.Y. Wang, D.H. Lee, M.R. D'Andrea, P.A. Peterson, R.P. Shank, A.B. Reitz, Beta-amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity: Implications for Alzheimer's disease pathology, J. Biol. Chem. 275 ( 2000) 56265632, doi:10.1074/jbc.275.8.5626.

[34] H.Y. Wang, D.H. Lee, C.B. Davis, R.P. Shank, Amyloid peptide Abeta(1-42) binds selectively and with picomolar affinity to alpha7 nicotinic acetylcholine receptors, J. Neurochem. 75 ( 2000) 1155-1161, doi:10.1046/j.1471-4159.2000.0751155.x.

[35] Q. Liu, H. Kawai, D.K. Berg, Beta-amyloid peptide blocks the response of alpha 7containing nicotinic receptors on hippocampal neurons, Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 4734-4739, doi:10.1073/pnas. 081553598.

[36] L. Pym, M. Kemp, V. Raymond-Delpech, S. Buckingham, C.A. Boyd, D. Sattelle,Subtype-specific actions of beta-amyloid peptides on recombinant human neuronal nicotinic acetylcholine receptors (alpha7, alpha4beta2, alpha3beta4) expressed in Xenopus laevis oocytes, Br. J. Pharmacol. 146 (2005) 964-971, doi:10.1038/sj.bjp.0706403.

[37] H.R. Parri, C.M. Hernandez, K.T. Dineley, Research update: Alpha7 nicotinic acetylcholine receptor mechanisms in Alzheimer's disease, Biochem. Pharmacol. 82 ( 2011) 931-942, doi:10.1016/j.bcp.2011.06.039.

[38] K.H. Forest, N. Alfulaij, K. Arora, R. Taketa, T. Sherrin, C. Todorovic, J.L.M. Lawrence, G.T. Yoshikawa, H.L. Ng, V.J. Hruby, R.A. Nichols, Protection against $\beta$ -amyloid neurotoxicity by a non-toxic endogenous N -terminal $\beta$ -amyloid fragment and its active hexapeptide core sequence, J. Neurochem. 144 (2018) 201217, doi:10.1111/jnc.14257.

[39] M. Lasala, C. Fabiani, J. Corradi, S. Antollini, C. Bouzat, Molecular modulation of human a7 nicotinic receptor by amyloid- $\beta$ peptides, Front. Cell. Neurosci. 13 (2019) 37, doi:10.3389/fncel.2019.00037.

[40] M.L. Giuffrida, F. Caraci, B. Pignataro, S. Cataldo, P. De Bona, V. Bruno, G. Molinaro, G. Pappalardo, A. Messina, A. Palmigiano, D. Garozzo, F. Nicoletti, E. Rizzarelli, A. Copani, Beta-amyloid monomers are neuroprotective, J. Neurosci. 29 (2009) 10582-10587, doi:10.1523/jneurosci.1736-09.2009.

[41] O. Hansson, S. Lehmann, M. Otto, H. Zetterberg, P. Lewczuk, Advantages and disadvantages of the use of the CSF amyloid $\beta$(A$\beta$)42/40 ratio in the diagnosis of Alzheimer's disease, Alzheimers Res. Ther. 11 (2019) 34, doi:10.1186/s13195-019-0485-0.

[42] L.W. Simpson, G.L. Szeto, H. Boukari, T.A. Good, J.B. Leach, Collagen hydrogel confinement of amyloid- $\beta$(A$\beta$) accelerates aggregation and reduces cytotoxic effects, Acta Biomater 112 (2020) 164-173, doi:10.1016/j.actbio.2020.05.030.

[43] H. Li, E. Huang, Y. Zhang, S.Y. Huang, Y. Xiao, HDOCK update for modeling proteinRNA/DNA complex structures, Protein Sci 31 (2022) e4441, doi:10.1002/pro.4441.

[44] J. Lee, X. Cheng, J.M. Swails, M.S. Yeom, P.K. Eastman, J.A. Lemkul, S. Wei, J. Buckner, J.C. Jeong, Y. Qi, S. Jo, V.S. Pande, D.A. Case, C.L. Brooks III, A.D. MacKerell Jr. J. B. Klauda, W. Im, CHARMM-GUI input generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM/OpenMM simulations using the CHARMM36 additive force field, J. Chem. Theory Comput. 12 (2016) 405-413, doi:10.1021/acs.jctc.5b00935.

[45] W.L. Jorgensen, J.D. Madura, Quantum and statistical mechanical studies of liquids. 25. Solvation and conformation of methanol in water, J. Am. Chem. Soc. 105 (1983) 1407-1413, doi:10.1021/ja00344a001.

[46] W.G. Hoover, Canonical dynamics: Equilibrium phase-space distributions, Phys. Rev. A 31 (1985) 1695-1697, doi:10.1103/PhysRevA.31.1695.

[47] J.R. Ray, A. Rahman, Statistical ensembles and molecular dynamics studies of anisotropic solids. II, J. Chem. Phys. 82 (1985) 4243-4247, doi:10.1063/1.448813.

[48] N. Ojaghlou, J. Airas, L.M. McRae, C.A. Taylor, B.R. Miller III, C.A. Parish, Understanding the structure and apo dynamics of the functionally active JIP1 fragment, J. Chem. Inf. Model. 61 ( 2021) 324-334, doi:10.1021/acs.jcim.0c01008.

[49] B. Hess, H. Bekker, H.J.C. Berendsen, J.G.E.M. Fraaije, LINCS: A linear constraint solver for molecular simulations, J. Comput. Chem. 18 ( 1997) 1463-1472, doi:10.1002/(SICI)1096-987X(199709)18:12 < 1463::AID-JCC4 > 3.0.CO;2-H.

[50] S. Miyamoto, P.A. Kollman, SETTLE: An analytical version of the SHAKE and RATTLE algorithm for rigid water models, J. Comput. Chem. 13 (1992) 952-962, doi:10.1002/jcc.540130805.

[51] Y. Qiu, A. Mekkat, H. Yu, S. Yigit, S. Hamaia, R.W. Farndale, D.L. Kaplan, Y.S. Lin, B. Brodsky, Collagen Gly missense mutations: Effect of residue identity on collagen structure and integrin binding, J. Struct. Biol. 203 (2018) 255-262, doi:10.1016/j.jsb.2018.05.003.

[52] G. Bussi, D. Donadio, M. Parrinello, Canonical sampling through velocity rescaling, J. Chem. Phys. 126 (2007) 014101, doi:10.1063/1.2408420.

[53] T. Zeiske, K.A. Stafford, R.A. Friesner, A.G. Palmer 3rd, Starting-structure dependence of nanosecond timescale intersubstate transitions and reproducibility of MDderived order parameters, Proteins 81 (2013) 499-509, doi:10.1002/prot.24209.

[54] J. Huang, S. Rauscher, G. Nawrocki, T. Ran, M. Feig, B.L. de Groot, H. Grubmüller, A.D. MacKerell, CHARMM36m: An improved force field for folded and intrinsically disordered proteins, Nat. Methods 14 (2017) 71-73, doi:10.1038/nmeth.4067.

[55] M.F. Adasme, K.L. Linnemann, S.N. Bolz, F. Kaiser, S. Salentin, V.J. Haupt, M. Schroeder, PLIP 2021: Expanding the scope of the protein-ligand interaction profiler to DNA and RNA, Nucleic Acids Res. 49 (2021) W530-W534, doi:10.1093/nar/gkab294.

[56] Y. Wang, Y. Liu, Y. Zhang, G. Wei, F. Ding, Y. Sun, Molecular insights into the oligomerization dynamics and conformations of amyloidogenic and nonamyloidogenic amylin from discrete molecular dynamics simulations, Phys. Chem. Chem. Phys. 24 (2022) 21773-21785, doi:10.1039/D2CP02851D.

[57] O.S. Smart, J.G. Neduvelil, X. Wang, B.A. Wallace, M.S. Sansom, HOLE: A program for the analysis of the pore dimensions of ion channel structural models, J. Mol. Graph. Model. 14 (1996) 354-360, doi:10.1016/s0263-7855(97)00009-x.

[58] E.F. Pettersen, T.D. Goddard, C.C. Huang, G.S. Couch, D.M. Greenblatt, E.C. Meng, T.E. Ferrin, UCSF Chimera-a visualization system for exploratory research and analysis, J. Comput. Chem. 25 (2004) 1605-1612, doi:10.1002/jcc.20084.

[59] W. Humphrey, A. Dalke, K. Schulten, VMD: Visual molecular dynamics, J. Mol. Graph. 14 (1996) 33-38, doi:10.1016/0263-7855(96)00018-5.

[60] R.E. Rigsby, A.B. Parker, Using the PyMOL application to reinforce visual understanding of protein structure, Biochem. Mol. Biol. Educ. 44 (2016) 433-437, doi:10.1002/bmb. 20966.

[61] R. Kumari, R. Kumar, A. Lynn, g_mmpbsa-a GROMACS tool for highthroughput MM-PBSA calculations, J. Chem. Inf. Model. 54 (2014) 1951-1962, doi:10.1021/ci500020m.

[62] E. Wang, H. Sun, J. Wang, Z. Wang, H. Liu, J.Z.H. Zhang, T. Hou, Endpoint binding free energy calculation with MM/PBSA and MM/GBSA: Strategies and applications in drug design, Chem. Rev. 119 (2019) 9478-9508, doi:10.1021/acs.chemrev.9b00055.

[63] Y.J. Sheng, Y.W. Yin, Y.Q. Ma, H.M. Ding, Improving the performance of MM/PBSA in protein-protein interactions via the screening electrostatic energy, J. Chem. Inf. Model. 61 (2021) 2454-2462, doi:10.1021/acs.jcim.1c00410.

[64] K. Huang, S. Luo, Y. Cong, S. Zhong, J.Z.H. Zhang, L. Duan, An accurate free energy estimator: Based on MM/PBSA combined with interaction entropy for protein-ligand binding affinity, Nanoscale 12 (2020) 10737-10750, doi:10.1039/C9NR10638C.

[65] B. Knapp, L. Ospina, C.M. Deane, Avoiding false positive conclusions in molecular simulation: The importance of replicas, J. Chem. Theory Comput. 14 (2018) 61276138, doi:10.1021/acs.jctc.8b00391.

[66] P. Auffinger, E. Westhof, RNA hydration: Three nanoseconds of multiple molecular dynamics simulations of the solvated tRNA(Asp) anticodon hairpin, J. Mol. Biol. 269 (1997) 326-341, doi:10.1006/jmbi.1997.1022.

[67] J. Chen, X. Liu, S. Zhang, J. Chen, H. Sun, L. Zhang, Q. Zhang, Molecular mechanism with regard to the binding selectivity of inhibitors toward FABP5 and FABP7 explored by multiple short molecular dynamics simulations and free energy analyses, Phys. Chem. Chem. Phys. 22 (2020) 2262-2275, doi:10.1039/C9CP05704H.

[68] L.M. Espinoza-Fonseca, Molecular docking of four $\beta$-amyloid _1-42 fragments on the a7 nicotinic receptor: Delineating the binding site of the A$\beta$ peptides, Biochem. Biophys. Res. Commun. 323 (2004) 1191-1196, doi:10.1016/j.bbrc.2004.08.218.

[69] D. Liu, J.V. de Souza, A. Ahmad, A.K. Bronowska, Structure, dynamics, and ligand recognition of human-specific CHRFAM7A (Dup a7) nicotinic receptor linked to neuropsychiatric disorders, Int. J. Mol. Sci. 22 (2021) 5466, doi:10.3390/ijms22115466.

[70] T.M. Tong, K. Arora, M.M. White, R.A. Nichols, Role of key aromatic residues in the ligand-binding domain of alpha7 nicotinic receptors in the agonist action of betaamyloid, J. Biol. Chem. 286 ( 2011) 34373-34381, doi:10.1074/jbc.M111.241299.

[71] N.L. Puskar, X. Xiu, H.A. Lester, D.A. Dougherty, Two neuronal nicotinic acetylcholine receptors, alpha4beta4 and alpha7, show differential agonist binding modes, J. Biol. Chem. 286 (2011) 14618-14627, doi:10.1074/jbc.M110.206565.

[72] N.A. Horenstein, T.J. McCormack, C. Stokes, K. Ren, R.L. Papke, Reversal of agonist selectivity by mutations of conserved amino acids in the binding site of nicotinic acetylcholine receptors, J. Biol. Chem. 282 (2007) 5899-5909, doi:10.1074/jbc.M609202200.

[73] M. Nys, D. Kesters, C. Ulens, Structural insights into Cys-loop receptor function and ligand recognition, Biochem. Pharmacol. 86 (2013) 1042-1053, doi:10.1016/j.bcp.2013.07.001.

[74] V. Bondarenko, M.M. Wells, Q. Chen, T.S. Tillman, K. Singewald, M.J. Lawless, J. Caporoso, N. Brandon, J.A. Coleman, S. Saxena, E. Lindahl, Y. Xu, P. Tang, Structures of highly flexible intracellular domain of human a7 nicotinic acetylcholine receptor, Nat. Commun. 13 (2022) 793, doi:10.1038/s41467-022-28400-x.

[75] E. Cecon, J. Dam, M. Luka, C. Gautier, A.M. Chollet, P. Delagrange, L. Danober, R. Jockers, Quantitative assessment of oligomeric amyloid $\beta$ peptide binding to a7 nicotinic receptor, Br. J. Pharmacol. 176 (2019) 3475-3488, doi:10.1111/bph.14688.

[76] K.T. Dineley, K.A. Bell, D. Bui, J.D. Sweatt, $\beta$-amyloid peptide activates a7 nicotinic acetylcholine receptors expressed in Xenopus oocytes, J. Biol. Chem. 277 (2002) 25056-25061, doi:10.1074/jbc.M200066200.

[77] R. Kayed, C.A. Lasagna-Reeves, Molecular mechanisms of amyloid oligomers toxicity, J. Alzheimers Dis. 33 (2013) S67-S78, doi:10.3233/jad-2012-129001.

[78] W. Jongbloed, K.A. Bruggink, M.I. Kester, P.J. Visser, P. Scheltens, M.A. Blankenstein, M.M. Verbeek, C.E. Teunissen, R. Veerhuis, Amyloid- $\beta$ oligomers relate to cognitive decline in Alzheimer's disease, J. Alzheimers Dis. 45 (2015) 35-43, doi:10.3233/jad-142136.

[79] E. Karran, B. De Strooper, The amyloid cascade hypothesis: Are we poised for success or failure? J. Neurochem. 139 (2016) 237-252, doi:10.1111/jnc.13632.

[80] R.R. Sokal, F.J. Rohlf, Biometry: The principles and Practice of Statistics in Biological Research, 4th ed., W.H. Freeman, New York, 2012.

[81] M.J. Thompson, F. Mansoub Bekarkhanechi, A. Ananchenko, H. Nury, J.E. Baenziger, A release of local subunit conformational heterogeneity underlies gating in a muscle nicotinic acetylcholine receptor, Nat. Commun. 15 (2024) 1803, doi:10.1038/s41467-024-46028-x.

[82] A. Sethi, J. Eargle, A.A. Black, Z. Luthey-Schulten, Dynamical networks in tRNA: Protein complexes, Proc. Natl. Acad. Sci. U.S.A. 106 (2009) 6620-6625, doi:10.1073/pnas.0810961106.

[83] J.R. López-Blanco, J.I. Aliaga, E.S. Quintana-Ortí P. Chacón, iMODS: Internal coordinates normal mode analysis server, Nucleic Acids Res. 42 (2014) W271-W276, doi:10.1093/nar/gku339.

[84] J.R. López-Blanco, J.I. Garzón, P. Chacón, iMod: Multipurpose normal mode analysis in internal coordinates, Bioinformatics 27 (2011) 2843-2850, doi:10.1093/bioinformatics/btr497.

[85] J.A. Kovacs, P. Chacón, R. Abagyan, Predictions of protein flexibility: First-order measures, Proteins 56 (2004) 661-668, doi:10.1002/prot. 20151.